Header Logo

Connection

ERNEST HAWK to Middle Aged

Back to Details
This is a "connection" page, showing publications ERNEST HAWK has written about Middle Aged.
ERNEST HAWK
Connection Strength
0.305
Middle Aged
  1. Recent American College of Physicians Guidance Statement for Screening Average-risk, Asymptomatic Adults for Colorectal Cancer. Cancer Prev Res (Phila). 2024 01 04; 17(1):1-5.
    View in: PubMed
    Score: 0.034
  2. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
    View in: PubMed
    Score: 0.018
  3. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205.
    View in: PubMed
    Score: 0.016
  4. Cancer chemoprevention: successes and failures. Clin Chem. 2013 Jan; 59(1):94-101.
    View in: PubMed
    Score: 0.016
  5. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes. 2024 Jan-Dec; 16(1):2399260.
    View in: PubMed
    Score: 0.009
  6. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004 Sep-Oct; 24(5B):3177-84.
    View in: PubMed
    Score: 0.009
  7. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center. J Natl Compr Canc Netw. 2024 05 10; 22(2 D).
    View in: PubMed
    Score: 0.009
  8. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
    View in: PubMed
    Score: 0.009
  9. The Performance of Colorectal Cancer Screening in Brazil: The First Two Years of the Implementation Program in Barretos Cancer Hospital. Cancer Prev Res (Phila). 2021 02; 14(2):241-252.
    View in: PubMed
    Score: 0.007
  10. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000 May; 9(5):523-7.
    View in: PubMed
    Score: 0.007
  11. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer. 2021 Jan; 29(1):97-105.
    View in: PubMed
    Score: 0.007
  12. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. Cancer Epidemiol Biomarkers Prev. 2020 04; 29(4):761-768.
    View in: PubMed
    Score: 0.006
  13. Characteristics of us adults attempting tobacco use cessation using e-cigarettes. Addict Behav. 2020 01; 100:106123.
    View in: PubMed
    Score: 0.006
  14. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One. 2019; 14(8):e0220814.
    View in: PubMed
    Score: 0.006
  15. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303.
    View in: PubMed
    Score: 0.006
  16. Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):486-494.
    View in: PubMed
    Score: 0.006
  17. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
    View in: PubMed
    Score: 0.006
  18. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 08 01; 4(8):1085-1092.
    View in: PubMed
    Score: 0.006
  19. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130.
    View in: PubMed
    Score: 0.005
  20. The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018 07; 67(7):1299-1305.
    View in: PubMed
    Score: 0.005
  21. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
    View in: PubMed
    Score: 0.005
  22. Germline Genetic Variants in the Wnt/?-Catenin Pathway as Predictors of Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):540-6.
    View in: PubMed
    Score: 0.005
  23. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
    View in: PubMed
    Score: 0.005
  24. Should CMS cover lung cancer screening for the fully informed patient? JAMA. 2014 Sep 24; 312(12):1193-4.
    View in: PubMed
    Score: 0.004
  25. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
    View in: PubMed
    Score: 0.004
  26. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med. 2013 Jun; 2(3):391-402.
    View in: PubMed
    Score: 0.004
  27. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611.
    View in: PubMed
    Score: 0.004
  28. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98.
    View in: PubMed
    Score: 0.004
  29. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91.
    View in: PubMed
    Score: 0.004
  30. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.
    View in: PubMed
    Score: 0.004
  31. Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903.
    View in: PubMed
    Score: 0.004
  32. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar; 34(3):569-79.
    View in: PubMed
    Score: 0.004
  33. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila). 2012 Jan; 5(1):61-72.
    View in: PubMed
    Score: 0.004
  34. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
    View in: PubMed
    Score: 0.004
  35. Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):415-6.
    View in: PubMed
    Score: 0.003
  36. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86.
    View in: PubMed
    Score: 0.003
  37. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96.
    View in: PubMed
    Score: 0.003
  38. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17.
    View in: PubMed
    Score: 0.003
  39. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21.
    View in: PubMed
    Score: 0.003
  40. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1.
    View in: PubMed
    Score: 0.003
  41. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8.
    View in: PubMed
    Score: 0.003
  42. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31.
    View in: PubMed
    Score: 0.003
  43. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 04; 99(7):545-57.
    View in: PubMed
    Score: 0.003
  44. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35.
    View in: PubMed
    Score: 0.003
  45. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
    View in: PubMed
    Score: 0.003
  46. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 01; 66(13):6851-60.
    View in: PubMed
    Score: 0.003
  47. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 2006 May; 15(5):1046-7.
    View in: PubMed
    Score: 0.002
  48. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005 Sep; 129(3):863-73.
    View in: PubMed
    Score: 0.002
  49. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80.
    View in: PubMed
    Score: 0.002
  50. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 01; 10(19):6502-11.
    View in: PubMed
    Score: 0.002
  51. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1250-2.
    View in: PubMed
    Score: 0.002
  52. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
    View in: PubMed
    Score: 0.002
  53. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst. 2002 Jul 03; 94(13):1001-9.
    View in: PubMed
    Score: 0.002
  54. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):201-7.
    View in: PubMed
    Score: 0.002
  55. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000 Jan; 6(1):78-89.
    View in: PubMed
    Score: 0.002
  56. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst. 1999 Apr 21; 91(8):691-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.